🔗 Share this article

As America continues making sweeping adjustments to its immunization schedules, an unexpected name has emerged somewhat surprisingly: Høeg, a US-based sports physician and public health researcher who initially gained attention by expressing skepticism about Covid vaccines during the pandemic and has zeroed in on alleged deaths after Covid vaccination in her brief tenure at the FDA.

Scheduled Shifts to Childhood Vaccine Program

Health officials were set to unveil major revisions to the childhood vaccination calendar in December, bringing the US with the Danish national calendar, sources say – a substantial departure that would put the US out of step with many the world with no evidence for improved outcomes. The planned update has been pushed back until the new year.

Instead of the director of the vaccine center, Høeg is set to speak at the meeting. She was recently named temporary leader of the FDA’s drug evaluation center, the fifth person to lead the office this calendar year.

A New Direction at the FDA

This interim role could signify a strengthened alliance between the drug and biologics branches as Dr. Høeg and Dr. Prasad consolidate power at the FDA – and it signals a increased emphasis upon reevaluating long-standing vaccines at the FDA.

Høeg has frequently advocated for halting some childhood shot schedules in the US so as to align more like the Danish model, a society with universal health coverage and a citizenry roughly the size of the state of Wisconsin.

In her initial comments, she has kept her attention on vaccines – usually the purview of Dr. Prasad, director of the FDA’s CBER – rather than drug regulation.

Concerns Over Background

Dr. Høeg has no obvious background in drug development, approval processes or management, which has been customary for past directors of the CBER. She has been employed at the FDA as a top consultant to the agency head and the vaccine center since earlier this year.

“It seems she lacks to have the requisite experience” for running the pharmaceutical oversight division, stated Jonathan Howard. “She has not conducted a clinical trial. She lacks experience in running a large organization. She has no expertise in pharmaceutical oversight.”

Previous commissioners of the center would “be deeply familiar with laws and regulations and the science of pharmaceutical innovation”, said a former acting FDA commissioner. “Objectively, she doesn’t have the kind of background that prior appointees who led CBER have had.”

The drug center has an vast portfolio at the FDA, Woodcock pointed out.

“Many people just focuses on the innovative therapies, but the generic drug division clears numerous generic medications. There’s a biologic copycat branch, OTC medication office and so forth, and each of these have to be managed,” Dr. Woodcock said. “The responsibility you don’t keep your eye on, that’s the thing that I always told people is going to cause problems.”

There is also, a major administrative component to the position, which manages over 5,000 staff members. “It is a enormous leadership role, if you perform it correctly,” she added.

Official Statement and Disputed Initiatives

Regarding questions about Dr. Høeg's credentials and whether this assignment signifies greater collaboration among FDA leaders on vaccines, a representative responded that the “concerns are based on flawed assumptions”.

“This background is consistent with the duties of her position,” the official stated, citing the period Dr. Høeg spent guiding the FDA commissioner on “medication safety and regulatory science, including computerized risk analysis and vaccine surveillance”.

As the temporary head, Dr. Høeg inherits the agency head's controversial expedited review system, a disputed rapid medication authorization process that allegedly concerned her preceding directors. “How are these therapies being selected for this fast-track system? Who is making the decisions?” Dr. Howard questioned. “There’s a lot of lack of transparency occurring at the agency right now.”

Overall, he remarked, “the Food and Drug Administration seems to be moving towards laxer oversight of pharmaceuticals, aside from shots.”

Established History on Immunizations

Concerning vaccines, Dr. Høeg has a more documented, if troubling, history, Howard have noted. She authored a research paper using unverified crowd-sourced reports to estimate the incidence of heart inflammation after Covid vaccination. She counseled the state of Florida chief medical officer Dr. Joseph Ladapo, who allegedly have changed statistics to imply COVID-19 vaccinations are riskier than they are.

Part of her “desired changes” for the current government featured changing regulations for recently developed shots and halting “optional” immunizations, she said post-election on a audio program. At the FDA, Dr. Høeg has allegedly suggested excluding adolescent males from obtaining COVID-19 vaccines.

“She’s an all-around true believer who commences with her preconceived notions and works backwards to fit the science in a highly misleading, fraudulent manner,” Dr. Howard stated.

Consolidating Power and a “Push for Payback”

Dr. Høeg aligned with fellow skeptics, {like|